tiprankstipranks
Exelixis (CH:EX9)
:EX9
Switzerland Market

Exelixis (EX9) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

EX9 Analyst Ratings

Hold
13Ratings
Hold
4 Buy
8 Hold
1 Sell
Based on 13 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EX9 Stock 12 Month Forecast

Average Price Target

Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is CHF42.27 with a high forecast of CHF52.39 and a low forecast of CHF33.56. The average price target represents a change from the last price of .
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
Highest Price TargetCHF52.39Average Price TargetCHF42.27Lowest Price TargetCHF33.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:EX9
Morgan Stanley
Morgan Stanley
CHF40.93CHF43.38
Hold
Assigned
07/23/26
Morgan Stanley Issues a Hold Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on CH:EX9
Goldman Sachs
Goldman Sachs
CHF40.93CHF52.39
Buy
Assigned
07/23/26
Exelixis (EXEL) Gets a Buy from Goldman Sachs
Barclays Analyst forecast on CH:EX9
Barclays
Barclays
CHF36.84CHF40.11
Hold
Reiterated
07/14/26
Barclays Remains a Hold on Exelixis (EXEL)
Wells Fargo
CHF32.74CHF40.11
Hold
Reiterated
07/13/26
Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)
RBC Capital Analyst forecast on CH:EX9
RBC Capital
RBC Capital
CHF35.2CHF37.65
Hold
Reiterated
07/07/26
Exelixis price target raised to $46 from $43 at RBC CapitalExelixis price target raised to $46 from $43 at RBC Capital
Truist Financial Analyst forecast on CH:EX9
Truist Financial
Truist Financial
CHF44.2CHF45.84
Hold
Reiterated
07/07/26
Exelixis price target raised to $56 from $54 at TruistExelixis price target raised to $56 from $54 at Truist
H.C. Wainwright Analyst forecast on CH:EX9
H.C. Wainwright
H.C. Wainwright
CHF45.84
Buy
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS
CHF35.2CHF42.57
Hold
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Bank of America Securities Analyst forecast on CH:EX9
Bank of America Securities
Bank of America Securities
CHF33.56
Sell
Reiterated
06/22/26
Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price
William Blair Analyst forecast on CH:EX9
William Blair
William Blair
Buy
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Kiora Pharmaceuticals (NASDAQ: KPRX) and MAIA Biotechnology, Inc. (NYSE MKT: MAIA)
Stifel Nicolaus Analyst forecast on CH:EX9
Stifel Nicolaus
Stifel Nicolaus
CHF36.02CHF38.47
Hold
Assigned
05/06/26
Exelixis price target raised to $47 from $44 at StifelExelixis price target raised to $47 from $44 at Stifel
Guggenheim Analyst forecast on CH:EX9
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
05/06/26
Guggenheim Remains a Hold on Exelixis (EXEL)
TD Cowen Analyst forecast on CH:EX9
TD Cowen
TD Cowen
CHF41.75CHF45.02
Buy
Assigned
05/05/26
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
Jefferies Analyst forecast on CH:EX9
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF38.47
Buy
Reiterated
03/25/26
Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)
Stephens Analyst forecast on CH:EX9
Unknown Analyst
Stephens
Not Ranked
Stephens
CHF49.11
Buy
Reiterated
02/11/26
Exelixis (EXEL) Receives a Buy from Stephens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:EX9
Morgan Stanley
Morgan Stanley
CHF40.93CHF43.38
Hold
Assigned
07/23/26
Morgan Stanley Issues a Hold Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on CH:EX9
Goldman Sachs
Goldman Sachs
CHF40.93CHF52.39
Buy
Assigned
07/23/26
Exelixis (EXEL) Gets a Buy from Goldman Sachs
Barclays Analyst forecast on CH:EX9
Barclays
Barclays
CHF36.84CHF40.11
Hold
Reiterated
07/14/26
Barclays Remains a Hold on Exelixis (EXEL)
Wells Fargo
CHF32.74CHF40.11
Hold
Reiterated
07/13/26
Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)
RBC Capital Analyst forecast on CH:EX9
RBC Capital
RBC Capital
CHF35.2CHF37.65
Hold
Reiterated
07/07/26
Exelixis price target raised to $46 from $43 at RBC CapitalExelixis price target raised to $46 from $43 at RBC Capital
Truist Financial Analyst forecast on CH:EX9
Truist Financial
Truist Financial
CHF44.2CHF45.84
Hold
Reiterated
07/07/26
Exelixis price target raised to $56 from $54 at TruistExelixis price target raised to $56 from $54 at Truist
H.C. Wainwright Analyst forecast on CH:EX9
H.C. Wainwright
H.C. Wainwright
CHF45.84
Buy
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS
CHF35.2CHF42.57
Hold
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Bank of America Securities Analyst forecast on CH:EX9
Bank of America Securities
Bank of America Securities
CHF33.56
Sell
Reiterated
06/22/26
Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price
William Blair Analyst forecast on CH:EX9
William Blair
William Blair
Buy
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Kiora Pharmaceuticals (NASDAQ: KPRX) and MAIA Biotechnology, Inc. (NYSE MKT: MAIA)
Stifel Nicolaus Analyst forecast on CH:EX9
Stifel Nicolaus
Stifel Nicolaus
CHF36.02CHF38.47
Hold
Assigned
05/06/26
Exelixis price target raised to $47 from $44 at StifelExelixis price target raised to $47 from $44 at Stifel
Guggenheim Analyst forecast on CH:EX9
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
05/06/26
Guggenheim Remains a Hold on Exelixis (EXEL)
TD Cowen Analyst forecast on CH:EX9
TD Cowen
TD Cowen
CHF41.75CHF45.02
Buy
Assigned
05/05/26
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
Jefferies Analyst forecast on CH:EX9
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF38.47
Buy
Reiterated
03/25/26
Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)
Stephens Analyst forecast on CH:EX9
Unknown Analyst
Stephens
Not Ranked
Stephens
CHF49.11
Buy
Reiterated
02/11/26
Exelixis (EXEL) Receives a Buy from Stephens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months
Robert BurnsH.C. Wainwright
Success Rate
16/19 ratings generated profit
84%
Average Return
+8.81%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +8.81% per trade.
1 Year
Success Rate
12/12 ratings generated profit
100%
Average Return
+44.20%
reiterated a buy rating 11 months ago
Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +44.20% per trade.
2 Years
Success Rate
12/12 ratings generated profit
100%
Average Return
+79.28%
reiterated a buy rating 11 months ago
Copying David Lebowitz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EX9 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
43
41
21
20
61
Hold
17
17
14
14
15
Sell
2
1
0
1
1
Strong Sell
0
0
0
0
0
total
62
59
35
35
77
In the current month, EX9 has received 61 Buy Ratings, 15 Hold Ratings, and 1 Sell Ratings. EX9 average Analyst price target in the past 3 months is 42.27.
Each month's total comprises the sum of three months' worth of ratings.

EX9 Financial Forecast

EX9 Earnings Forecast

Next quarter’s earnings estimate for EX9 is CHF0.69 with a range of CHF0.62 to CHF0.74. The previous quarter’s EPS was CHF0.70. EX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for EX9 is CHF0.69 with a range of CHF0.62 to CHF0.74. The previous quarter’s EPS was CHF0.70. EX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Sales Forecast

Next quarter’s sales forecast for EX9 is CHF514.03M with a range of CHF496.58M to CHF540.76M. The previous quarter’s sales results were CHF493.36M. EX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.
Next quarter’s sales forecast for EX9 is CHF514.03M with a range of CHF496.58M to CHF540.76M. The previous quarter’s sales results were CHF493.36M. EX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Stock Forecast FAQ

What is CH:EX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 42.27.
    What is CH:EX9’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:EX9, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Exelixis a Buy, Sell or Hold?
        Exelixis has a consensus rating of Hold, which is based on 4 buy ratings, 8 hold ratings and 1 sell ratings.
          What is Exelixis’s share price target?
          The average share price target for Exelixis is 42.27. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF52.39 ,and the lowest forecast is CHF33.56. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Exelixis?
            Exelixis’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Exelixis?
              To buy shares of CH:EX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.